Clinical Trial Update: A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. [Phase 3]

View source ↗

Summary

Pfizer's RSVpreF Phase 3 study aims to evaluate safety and immune response in adults at high risk for severe Respiratory Syncytial Virus infection. The trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVpreF

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus (RSV) | Phase 3 | Status: NOT_YET_RECRUITING